PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class ...
PCSK9 antibodies effectively lower the LDL-cholesterol level and, therefore, address an unmet clinical need in patients with either refractory hypercholesterolaemia, statin intolerance, or an elevated ...
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of cholesterol from the blood by decreasing the density of low-density lipoprotein receptors (LDLRs) on hepatic cells.
High levels of low-density lipoproteins, parcels of lipids and protein that carry cholesterol, are a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by ...
This study is led by professor Jingsong Ou(Division of Cardiac Surgery, Cardiovascular Diseases Institute, The First Affiliated Hospital, Sun Yat-sen University) and professor Zhi-Jun Ou (Division of ...
A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...
Recent studies on a group of PCSK enzymes could have a positive impact on health, from cholesterol to osteoporosis. Recent studies conducted at the Institut de recherches cliniques de Montréal (IRCM) ...
Elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been associated with adverse outcomes in patients hospitalized for sepsis. PCSK9 loss-of-function (LOF) variants area ...
High levels of low-density lipoproteins, parcels of lipids and protein that carry cholesterol, are a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by ...
How does PCSK9 function and what is the impact of this protein on cardiovascular disease? A research team coordinated by Dr. Nabil G. Seidah, researcher at the IRCM and at Université de Montréal, has ...
Barcelona, Spain - 27 Aug 2017: PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today.1 The findings suggest ...
High LDL a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by targeting the protein PCSK9. Scientists now report on an investigation into why experiments on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results